Related Articles
Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival
EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients
Determination of EGFR and KRAS mutational status in Greek non‑small‑cell lung cancer patients
Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG‑510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL‑XL